Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Vaishali Sanchorawala MD

Vaishali Sanchorawala MD

Professor of Medicine, Director, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts

Dr. Vaishali Sanchorawala is the Professor of Medicine and Director of the Amyloidosis Center of Boston University School of Medicine and Boston Medical Center. She has been one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has been published in many peer-reviewed journals, which has resulted in the evolution of the standard of care for these patients. She is currently heading several clinical trials in the treatment of AL amyloidosis. She serves on the executive steering committee of the Amyloidosis Research Consortium, the board of the International Society of Amyloidosis as secretary, chair of the membership committee of the International Society of Amyloidosis and as an associate editor of Amyloid, Journal of Protein Folding Disorders. She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in AL amyloidosis.


Research Support/P.I.: Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion
Consultant:  Pfizer, Janssen, Attralus
Scientific Advisory Board: Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZenec